Zexu Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zexu Li has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Teng Fei
Interdisciplinary Research Center for Brain-Computer Interface, Key Laboratory of Bioresource Research and Development of Liaoning Province, College of Life and Health Sciences, Northeastern University, Shenyang 110819, China
2 shared publications - Chen Ding
Department of Pathogenic Microbiology, School of Basic Medical Science, China Medical University, Shenyang, China
1 shared publication - Chengcheng Meng
Department of Pathology, The Fourth People’s Hospital of Shenyang, Shenyang, China
1 shared publication - Daming Gao
Key Laboratory of Multi-Cell Systems, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai 200031, China; University of Chinese Academy of Sciences, Number 19A Yuquan Road, Beijing 100049, China; Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China
1 shared publication - Haijiao Zhang
College of Life and Health Science, Northeastern University, Shenyang 110819, China
1 shared publication - Hongyi Yin
College of Life and Health Sciences, Northeastern University, Shenyang, China
1 shared publication
Latest Publications
- Open Access
- 4 July 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (16)
CDKL3 is a targetable regulator of cell cycle progression in cancers
Cell cycle regulation is largely abnormal in cancers. Molecular understanding and therapeutic targeting of the aberrant cell cycle are essential. Here, we identified that an underappreciated serine/threonine kinase, cyclin-dependent kinase–like 3 (CDKL3), crucially drives rapid cell cycle progression and cell growth in cancers. With regard to mechanism, CDKL3 localizes in the nucleus and associates with specific cyclin to directly phosphorylate retinoblastoma (Rb) for quiescence exit. In parallel, CDKL3 prevents the ubiquitin-proteasomal degradation of cyclin-dependent kinase 4 (CDK4) by direct phosphorylation on T172 to sustain G 1 phase advancement. The crucial function of CDKL3 in cancers was demonstrated both in vitro and in vivo. We also designed, synthesized, and characterized a first-in-class CDKL3-specific inhibitor, HZ1. HZ1 exhibits greater potency than CDK4/6 inhibitor in pan-cancer treatment by causing cell cycle arrest and overcomes acquired resistance to CDK4/6 inhibitor. In particular, CDKL3 has significant clinical relevance in colon cancer, and the effectiveness of HZ1 was demonstrated by murine and patient-derived cancer models. Collectively, this work presents an integrated paradigm of cancer cell cycle regulation and suggests CDKL3 targeting as a feasible approach in cancer treatment.
- 4 July 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (16)
Open AccessCDKL3 is a targetable regulator of cell cycle progression in cancers
Cell cycle regulation is largely abnormal in cancers. Molecular understanding and therapeutic targeting of the aberrant cell cycle are essential. Here, we identified that an underappreciated serine/threonine kinase, cyclin-dependent kinase–like 3 (CDKL3), crucially drives rapid cell cycle progression and cell growth in cancers. With regard to mechanism, CDKL3 localizes in the nucleus and associates with specific cyclin to directly phosphorylate retinoblastoma (Rb) for quiescence exit. In parallel, CDKL3 prevents the ubiquitin-proteasomal degradation of cyclin-dependent kinase 4 (CDK4) by direct phosphorylation on T172 to sustain G 1 phase advancement. The crucial function of CDKL3 in cancers was demonstrated both in vitro and in vivo. We also designed, synthesized, and characterized a first-in-class CDKL3-specific inhibitor, HZ1. HZ1 exhibits greater potency than CDK4/6 inhibitor in pan-cancer treatment by causing cell cycle arrest and overcomes acquired resistance to CDK4/6 inhibitor. In particular, CDKL3 has significant clinical relevance in colon cancer, and the effectiveness of HZ1 was demonstrated by murine and patient-derived cancer models. Collectively, this work presents an integrated paradigm of cancer cell cycle regulation and suggests CDKL3 targeting as a feasible approach in cancer treatment.
- Open Access
- 1 September 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (3) , 100653
An in silico drug repositioning workflow for host-based antivirals
- 1 September 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (3) , 100653
Open AccessAn in silico drug repositioning workflow for host-based antivirals